Core Insights - Boji Pharmaceutical's stock price increased by 2.19% on November 13, reaching 10.74 CNY per share, with a total market capitalization of 4.143 billion CNY [1] - The company has seen a year-to-date stock price increase of 23.19%, with a 7.51% rise over the last five trading days [1] Financial Performance - For the period from January to September 2025, Boji Pharmaceutical reported a revenue of 584 million CNY, representing a year-on-year growth of 5.06% [2] - The net profit attributable to shareholders was 21.9139 million CNY, which reflects a significant decrease of 49.36% compared to the previous year [2] Business Overview - Boji Pharmaceutical specializes in providing preclinical research services, clinical research services, technology transfer services, and consulting services related to new drug development [1] - The revenue composition of the company includes 80.18% from clinical research services, 11.31% from preclinical research services, 6.50% from other consulting services, and 2.02% from supplementary services [1] Shareholder Information - As of September 30, the number of shareholders for Boji Pharmaceutical was 29,600, an increase of 18.91% from the previous period [2] - The average number of circulating shares per shareholder decreased by 15.21% to 9,497 shares [2] Dividend Information - Since its A-share listing, Boji Pharmaceutical has distributed a total of 27.7583 million CNY in dividends, with 12.0783 million CNY distributed over the last three years [3]

Core Viewpoint - Oriental Bio's stock price has shown fluctuations, with a recent increase of 2.10% to 27.75 CNY per share, while the company has experienced a year-to-date decline of 5.39% [1] Financial Performance - For the period from January to September 2025, Oriental Bio reported a revenue of 672 million CNY, reflecting a year-on-year growth of 2.16% [2] - The company recorded a net profit attributable to shareholders of -213 million CNY, which is an improvement of 18.89% compared to the previous period [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Oriental Bio was 13,300, a decrease of 3.93% from the previous period [2] - The average number of circulating shares per shareholder increased by 4.09% to 15,170 shares [2] Dividend Distribution - Since its A-share listing, Oriental Bio has distributed a total of 1.607 billion CNY in dividends, with 336 million CNY distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the fourth largest circulating shareholder is Rongtong Health Industry Flexible Allocation Mixed A/B, holding 2.8 million shares, a decrease of 1.7001 million shares from the previous period [3] - Hong Kong Central Clearing Limited is the sixth largest shareholder, with 1.4675 million shares, an increase of 139,400 shares [3] - The Southern Science and Technology Innovation Board 3-Year Open Mixed Fund holds 780,900 shares, unchanged from the previous period [3]

Core Viewpoint - Huason Pharmaceutical's stock has shown a significant increase this year, with a year-to-date rise of 31.24%, indicating strong market interest and performance [2]. Group 1: Stock Performance - As of November 12, Huason Pharmaceutical's stock price rose by 2.05% to 16.95 CNY per share, with a market capitalization of 7.078 billion CNY [1]. - The stock has experienced a 3.99% increase over the last five trading days and a 1.13% increase over the last 20 days, while it has decreased by 5.65% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Huason Pharmaceutical reported a revenue of 626 million CNY, reflecting a year-on-year growth of 1.90%, while the net profit attributable to shareholders was 72.4556 million CNY, a decrease of 2.84% year-on-year [3]. - The company has distributed a total of 192 million CNY in dividends since its A-share listing, with 100 million CNY distributed in the last three years [4]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased to 33,100, with an average of 9,063 circulating shares per person, a slight decrease of 0.83% [3]. - The fifth largest circulating shareholder, Hong Kong Central Clearing Limited, reduced its holdings by 1.4123 million shares to 2.6207 million shares [4]. Group 4: Business Overview - Huason Pharmaceutical, established on November 4, 1996, operates in the pharmaceutical industry, focusing on research, production, and sales, with a revenue composition that includes 34.24% from ENT medications, 23.16% from digestive system medications, and 18.37% from psychiatric medications [2]. - The company is categorized under the pharmaceutical and biological industry, specifically in traditional Chinese medicine and generic drugs [2].

Company Overview - Zhejiang Anglikang Pharmaceutical Co., Ltd. was established on December 30, 2001, and listed on October 23, 2018. The company is engaged in the research, production, and sales of chemical raw materials and preparations [1] - The main business revenue composition includes preparations (43.46%), raw materials (39.82%), specialty intermediates (12.44%), others (3.72%), and pharmaceutical excipients (0.56%) [1] Stock Performance - As of November 12, Anglikang's stock price increased by 2.02%, reaching 43.50 CNY per share, with a total market capitalization of 8.775 billion CNY [1] - Year-to-date, Anglikang's stock price has risen by 233.13%, with an 8.42% increase over the last five trading days and a 5.58% increase over the last 20 days, while it has decreased by 17.97% over the last 60 days [1] Financial Performance - For the period from January to September 2025, Anglikang reported a revenue of 1.055 billion CNY, a year-on-year decrease of 5.92%, while the net profit attributable to shareholders was 77.6899 million CNY, reflecting a year-on-year increase of 55.59% [2] - The company has distributed a total of 341 million CNY in dividends since its A-share listing, with 108 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, Anglikang had 28,500 shareholders, an increase of 54.58% from the previous period, with an average of 6,493 circulating shares per shareholder, a decrease of 35.31% [2] - Notable institutional shareholders include Guangfa Medical Healthcare Stock A, which holds 3.3384 million shares, and several new entrants among the top ten circulating shareholders [3]

Core Viewpoint - Kanghui Co., Ltd. has shown a significant stock price increase of 64.07% year-to-date, indicating strong market interest and potential growth in the pharmaceutical sector [2]. Financial Performance - As of September 30, Kanghui Co., Ltd. reported a revenue of 356 million yuan, a year-on-year decrease of 11.97%, and a net profit attributable to shareholders of -133 million yuan, reflecting a substantial decline of 246.07% [2]. - The company has cumulatively distributed 54.23 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Market Activity - The stock price of Kanghui Co., Ltd. rose by 2.04% on November 11, reaching 23.56 yuan per share, with a trading volume of 23.57 million yuan and a turnover rate of 1.01% [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent instance on June 16, where it recorded a net purchase of 7.7 million yuan [2]. Shareholder Information - As of September 30, the number of shareholders for Kanghui Co., Ltd. was 9,458, a decrease of 21.15% from the previous period, while the average circulating shares per person increased by 26.82% to 10,560 shares [2]. Business Overview - Kanghui Co., Ltd., established on December 24, 2009, and listed on April 21, 2017, is primarily engaged in the research, development, production, and sales of traditional Chinese medicine, with its main business revenue composition being 60.68% from pharmaceutical manufacturing and 36.79% from pharmaceutical distribution [2]. - The company operates within the pharmaceutical and biotechnology sector, specifically in the traditional Chinese medicine sub-sector [2].

Core Viewpoint - Oriental Bio's stock price has shown fluctuations, with a recent increase of 2.05% and a year-to-date decline of 6.75%, indicating potential volatility in the market [1] Financial Performance - For the period from January to September 2025, Oriental Bio reported a revenue of 672 million yuan, reflecting a year-on-year growth of 2.16% [2] - The company experienced a net profit attributable to shareholders of -213 million yuan, which is an improvement of 18.89% compared to the previous period [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Oriental Bio was 13,300, a decrease of 3.93% from the previous period [2] - The average number of circulating shares per shareholder increased by 4.09% to 15,170 shares [2] Dividend Distribution - Since its A-share listing, Oriental Bio has distributed a total of 1.607 billion yuan in dividends, with 336 million yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the fourth largest circulating shareholder is Rongtong Health Industry Flexible Allocation Mixed A/B, holding 2.8 million shares, a decrease of 1.7001 million shares from the previous period [3] - Hong Kong Central Clearing Limited is the sixth largest shareholder, increasing its holdings by 139,400 shares to 1.4675 million shares [3] - The Southern Science and Technology Innovation Board 3-Year Open Mixed Fund maintained its holding of 780,900 shares, while the Medical Device ETF entered as a new shareholder with 757,900 shares [3]

Core Insights - The stock price of Anglikon increased by 2.07% on November 11, reaching 42.33 CNY per share, with a total market capitalization of 8.539 billion CNY [1] - Year-to-date, Anglikon’s stock has risen by 224.17%, with a recent 3.67% increase over the last five trading days [1] - For the first nine months of 2025, Anglikon reported a revenue of 1.055 billion CNY, a year-on-year decrease of 5.92%, while net profit attributable to shareholders increased by 55.59% to 77.6899 million CNY [2] Financial Performance - Anglikon has been listed on the stock market since October 23, 2018, and has a primary business focus on the research, production, and sales of chemical raw materials and formulations [1] - The revenue composition of Anglikon includes 43.46% from formulations, 39.82% from raw materials, 12.44% from specialty intermediates, 3.72% from others, and 0.56% from pharmaceutical excipients [1] - Cumulative cash dividends since the A-share listing amount to 341 million CNY, with 108 million CNY distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, Anglikon had 28,500 shareholders, an increase of 54.58% from the previous period, with an average of 6,493 circulating shares per shareholder, a decrease of 35.31% [2] - Notable institutional shareholders include Guangfa Medical Healthcare Stock A, which increased its holdings by 95,050 shares, and new entrants such as Huatai-PineBridge Innovation Medical Mixed A [3]

Core Viewpoint - The stock of Haishike has shown a significant increase of 64.01% year-to-date, despite a recent decline of 2.96% over the past five trading days, indicating volatility in its performance [1][2]. Financial Performance - For the period from January to September 2025, Haishike achieved a revenue of 3.3 billion yuan, representing a year-on-year growth of 19.95%. However, the net profit attributable to shareholders decreased by 22.66% to 295 million yuan [2]. - Cumulatively, Haishike has distributed 3.673 billion yuan in dividends since its A-share listing, with 687 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Haishike increased by 12.87% to 12,900, with an average of 37,342 circulating shares per shareholder, down by 11.40% [2]. - The top ten circulating shareholders include several institutional investors, with notable increases in holdings from entities such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited [3]. Stock Market Activity - On November 10, Haishike's stock price rose by 2.04% to 54.09 yuan per share, with a trading volume of 123 million yuan and a turnover rate of 0.48%. The total market capitalization reached 60.576 billion yuan [1]. - The net outflow of main funds was 237,700 yuan, while large orders showed a mixed trend with 9.09 million yuan in purchases and 10.61 million yuan in sales [1]. Business Overview - Haishike Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sales of chemical pharmaceuticals, with its main revenue sources being anesthetic products (39.81%), cooperative product-related income (23.59%), and other therapeutic areas [1]. - The company is categorized under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and formulations, and is involved in various concept sectors including Helicobacter pylori, hypertension treatment, and innovative drugs [1].

Core Points - Junyao Health's stock price increased by 2.01% on November 10, reaching 7.62 CNY per share with a market capitalization of 4.576 billion CNY [1] - The company has seen a year-to-date stock price increase of 22.67% and has appeared on the stock market's "Dragon and Tiger List" 11 times this year [2] - As of September 30, 2025, Junyao Health reported a revenue of 1.095 billion CNY, a year-on-year decrease of 6.95%, and a net profit loss of 2.3688 million CNY, a decrease of 104.79% [2] Financial Performance - The company has a total market capitalization of 4.576 billion CNY and a trading volume of 33.3247 million CNY on November 10 [1] - The main business revenue composition includes probiotic beverages (34.11%), supply chain (34.07%), probiotic foods (21.98%), and other beverages and foods (9.55%) [2] - Cumulative cash dividends since the A-share listing amount to 365 million CNY, with 132 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 19.52% to 34,300, while the average circulating shares per person increased by 24.25% to 17,487 shares [2] - Tianhong Zhongzheng Food and Beverage ETF is among the top ten circulating shareholders, holding 948,500 shares, an increase of 11.67% from the previous period [3]

Core Viewpoint - The stock of Haishike experienced a decline of 2.01% on November 7, with a current price of 52.77 yuan per share and a total market capitalization of 59.098 billion yuan, despite a year-to-date increase of 60.01% [1] Financial Performance - For the period from January to September 2025, Haishike reported a revenue of 3.3 billion yuan, representing a year-on-year growth of 19.95%, while the net profit attributable to shareholders decreased by 22.66% to 295 million yuan [2] - Cumulative cash dividends since the A-share listing amount to 3.673 billion yuan, with 687 million yuan distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 12.87% to 12,900, with an average of 37,342 circulating shares per shareholder, a decrease of 11.40% [2] - The top ten circulating shareholders include various funds, with notable increases in holdings from several institutional investors [3]